Using two primary CRC chemotherapeutics, 5-fluorouracil (5FU) and oxaliplatin, we established and validated resistant cell models to investigate whether WBP1 targeting could restore drug sensitivity. This evidence concerns the gene WBP1 and colorectal carcinoma.